ImmunoCellular Therapeutics Granted Monoclonal Antibody Technology Patent

LOS ANGELES--(Business Wire)--
ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC)(IMUC), a biotechnology company,
announced the issuance of a U.S. patent relating to the company`s monoclonal
antibody therapeutics. Patent No. 7,498,129 entitled "Myeloma Cell and Ovarian
Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof," covers
the use of IMUC`s antibodies to measure the effectiveness of the company`s
proposed treatment of multiple myeloma and ovarian cancer using the company`s
proprietary molecular antibodies. This builds on IMUC`s existing patent
portfolio covering technologies for both the detection and the treatment of
multiple types of cancer.

"This patent provides additional strength to the growing intellectual property
position that we are building around our antibody technologies for the detection
and the treatment of cancer," stated Manish Singh, Ph.D., president and chief
executive officer of IMUC. "We are actively exploring potential partnering
opportunities to enable us to bring these promising technologies through
clinical testing and commercialization."

"I am very encouraged by the preclinical data that we`re observing with these
antibodies, most notably their high specificity for binding to multiple myeloma
and ovarian cancer, and believe that they could represent a major step forward
in the treatment of certain cancers," stated Cohava Gelber, Ph.D., inventor of
the antibody technology and scientific advisor to IMUC. "With approximately
22,000 new cases of ovarian cancer each year and with more than 63,000 people
living with multiple myeloma, both of these cancers would greatly benefit from
more effective treatment alternatives."

IMUC, through its acquisition of monoclonal antibody-related technology from
Molecular Discoveries LLC, has several novel monoclonal antibodies. ICT-109, the
company`s lead antibody product candidate, is a monoclonal antibody targeting
small cell lung cancer (SCLC) and pancreatic cancer. This candidate is currently
in pre-clinical development, and the company plans to couple it with a
diagnostic kit to prescreen patients for the specific antigens that bind to
ICT-109. ICT-109 has demonstrated encouraging preliminary data in pre-clinical
studies and with appropriate support from a corporate partner or licensee, could
be ready to enter clinical trials in 2010 for SCLC and pancreatic cancer
indications.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune
based therapies for the treatment of brain and other cancers. The company`s "off
the shelf" therapeutic vaccine product candidate targeting cancer stem cells for
multiple cancer indications is expected to enter clinical trials during the
third quarter of 2009. IMUC is in pre-clinical development of a monoclonal
antibody product candidate for the treatment of small cell lung cancer and
pancreatic cancer, and is also evaluating its platform technology for monoclonal
antibody discovery using differential immunization for diagnosing and treating
multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject
to a number of risks and uncertainties, including without limitation the risk
that patents issued for IMUC`s monoclonal antibody product candidates may not be
enforceable or may not provide commercially significant protection for these
candidates; the need to confirm preliminary pre-clinical data for IMUC`s lead
monoclonal antibody and other monoclonal antibody product candidates; the risks
associated with pre-clinical and clinical development of molecular antibody and
other product candidates; the need for substantial additional capital to fund
development of product candidates beyond their initial clinical or pre-clinical
stages; and the potential inability to secure corporate partners or licensees
for development of the monoclonal antibody product candidates. Additional risks
and uncertainties are described in IMUC`s most recently filed SEC documents,
such as its most recent annual report on Form 10-KSB, all quarterly reports on
Form 10-Q and any current reports on Form 8-K, IMUC undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.

ImmunoCellular Therapeutics, Ltd.
Jennifer Cook Williams
Investor Relations
360-668-3701

Copyright Business Wire 2009